Clinical trial
Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant…
NCT00235482 · Viralytics, Industry · Completed
Key facts
| NCT number | NCT00235482 |
|---|---|
| Title | Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02) |
| Official title | Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02) |
| Acronym | PXS-X02 |
| Lead sponsor | Viralytics, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Drug |
| Interventions | Coxsackievirus A21 |
| Enrollment | 3 |
| Start date | Nov 8, 2005 |
| Primary completion | Apr 21, 2006 |
| Completion | Apr 21, 2006 |
| First posted | Oct 10, 2005 |
| Last update posted | Jun 27, 2019 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: